Advances in anti-BRAF therapies for lung cancer

Giandomenico Roviello; Alberto D'Angelo; Marianna Sirico; Matteo Pittacolo; Felipe Umpierre Conter; Navid Sobhani

doi:10.1007/s10637-021-01068-8

Advances in anti-BRAF therapies for lung cancer

Giandomenico Roviello, Alberto D'Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

Research output: Contribution to journal › Review article › peer-review

26 Citations (SciVal)

Abstract

Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0-3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.

Original language	English
Pages (from-to)	879-890
Number of pages	12
Journal	Investigational New Drugs
Volume	39
Issue number	3
Early online date	21 Jan 2021
DOIs	https://doi.org/10.1007/s10637-021-01068-8
Publication status	Published - 30 Jun 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Keywords

BRAF
Lung cancer
V600

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10637-021-01068-8Licence: CC BY

Cite this

@article{35f1570838634eacafd51ab993718a4e,

title = "Advances in anti-BRAF therapies for lung cancer",

abstract = "Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0-3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.",

keywords = "BRAF, Lung cancer, V600",

author = "Giandomenico Roviello and Alberto D'Angelo and Marianna Sirico and Matteo Pittacolo and Conter, {Felipe Umpierre} and Navid Sobhani",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = jun,

day = "30",

doi = "10.1007/s10637-021-01068-8",

language = "English",

volume = "39",

pages = "879--890",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - Advances in anti-BRAF therapies for lung cancer

AU - Roviello, Giandomenico

AU - D'Angelo, Alberto

AU - Sirico, Marianna

AU - Pittacolo, Matteo

AU - Conter, Felipe Umpierre

AU - Sobhani, Navid

PY - 2021/6/30

Y1 - 2021/6/30

N2 - Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0-3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.

AB - Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0-3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.

KW - BRAF

KW - Lung cancer

KW - V600

UR - http://www.scopus.com/inward/record.url?scp=85099656526&partnerID=8YFLogxK

U2 - 10.1007/s10637-021-01068-8

DO - 10.1007/s10637-021-01068-8

M3 - Review article

C2 - 33474634

SN - 0167-6997

VL - 39

SP - 879

EP - 890

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Advances in anti-BRAF therapies for lung cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this